SAC Meeting Calendar

The SAC Tracker Background Analysis is available in this calendar until 10 days after the meeting is held.

 
 

Newest Meeting Announcements

Newest Background Analyses

Featured
Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AAC jessica adams Comment
AUG 3 AAC
Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AAC jessica adams Comment

sNDAs for XELJANZ (tofacitinib) and XELJANZ XR (tofacitinib) by Pfizer for the treatment of adult patients with active psoriatic arthritis

Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
JUL 26 AADPAC-DSRM
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment

Intellipharmaceutics Corp.'s, oxycodone hydrochloride extended-release oral tablets

Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Featured
Background Analysis FDA, AADPAC, DSRM jessica adams Comment
Background Analysis FDA, AADPAC, DSRM jessica adams Comment
SEP 14 AADPAC-DSRM
Background Analysis FDA, AADPAC, DSRM jessica adams Comment
Background Analysis FDA, AADPAC, DSRM jessica adams Comment

Review of pediatric study of Butrans (buprenorphine transdermal) by Purdue Pharma L.P. for management of pain

Background Analysis FDA, AADPAC, DSRM jessica adams Comment
Background Analysis FDA, AADPAC, DSRM jessica adams Comment
Background Analysis FDA, ODAC jessica adams Comment
Background Analysis FDA, ODAC jessica adams Comment
SEP 19 ODAC
Background Analysis FDA, ODAC jessica adams Comment
Background Analysis FDA, ODAC jessica adams Comment

sNDA for SUTENT (sunitinib malate), represented by Pfizer, Inc. (authorized U.S. agent), proposed for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

Background Analysis FDA, ODAC jessica adams Comment
Background Analysis FDA, ODAC jessica adams Comment

Newest Briefing Summaries

Newest Results Wires

Featured
Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment
AUG 3 AAC
Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment

sNDAs for XELJANZ (tofacitinib) and XELJANZ XR (tofacitinib) by Pfizer for the treatment of adult patients with active psoriatic arthritis

Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment
AUG 2 AAC
Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment

Janssen's sirukumab injection (proposed trade name PLIVENSIA) for certain patients with rheumatoid arthritis

Briefing Summary FDA, AAC jessica adams Comment
Briefing Summary FDA, AAC jessica adams Comment
Featured
Results Wire HHS, ACHDNC jessica adams Comment
Results Wire HHS, ACHDNC jessica adams Comment
AUG 3-4 ACHDNC
Results Wire HHS, ACHDNC jessica adams Comment
Results Wire HHS, ACHDNC jessica adams Comment

Heritable Disorders in Newborns and Children

Results Wire HHS, ACHDNC jessica adams Comment
Results Wire HHS, ACHDNC jessica adams Comment
Results Wire FDA, AAC jessica adams Comment
Results Wire FDA, AAC jessica adams Comment
AUG 3 AAC
Results Wire FDA, AAC jessica adams Comment
Results Wire FDA, AAC jessica adams Comment

sNDAs for XELJANZ (tofacitinib) and XELJANZ XR (tofacitinib) by Pfizer for the treatment of adult patients with active psoriatic arthritis

Results Wire FDA, AAC jessica adams Comment
Results Wire FDA, AAC jessica adams Comment

Search by Tag